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Pigmentation in mammals is under complex genetic control. Amongst the genes involved in 
this process, those encoding tyrosinase and the tyrosinase-related-proteins 1 and 2 have been well 
characterized and share a number of features. Recently, the murine tyosinase-related-protein-2 gene 
was shown to encode dopachrome-tautomerase activity and was mapped to the slaty locus. Human 
tyrosinase and tyrosinase-related-protein-1 genes have been isolated and demonstrate a high degree 
of similarity with their murine counterparts. However, there has been limited data regarding the 
existence of a human homologue for tyrosinase-related-protein-2 and its relationship to the other 
tyrosinase-related proteins. In this study, we report the molecular isolation of a cDNA encoding a 
human homologue of the murine tyrosinase-related-protein-2/dopachrome tautomerase. We have 
characterized its expression in human melanocytic cells and have analyzed the relationship between 
dopachrome tautomerase and tyrosinase activities with the level of visible pigmentation in these 
cells. TYRP2 has been mapped to the chromosomal region 13q32, thus extending a region of 
synteny with mouse-chromosome 14. 
Much recent progress has been made in the understand- 
ing of the molecular mechanisms that regulate melanogen- 
esis. This process occurs in the melanosomes which are spe- 
cialized subcellular organelles within the melanocytes. Mela- 
nin results from the hydroxylation of L-tyrosine to L-dihy- 
droxyphenylalanine @-Dopa), and the subsequent oxidation 
of L-Dopa to L-dopaquinone. Until recently, tyrosinase [ 13 
was thought to be the only enzyme involved in this process. 
However, the many well-described mouse mutations which 
affect hair color had suggested that melanogenesis was the 
result of multiple interacting genes and regulatory factors [2]. 
The complexity of this process has been illustrated by the 
concomitant isolation of cDNA clones for tyrosinase and ad- 
ditional tyrosinase-related proteins. These molecules define 
a new family of proteins sharing structural primary sequence 
similarity. Moreover, some of the murine hair color pheno- 
types result from mutations in the tyrosinase and tyrosinase- 
related-protein genes, which have helped to distinguish these 
various pigmentation genes and the proteins that they encode. 
One such protein, the enzyme dopachrome tautomerase, 
has been the subject of much controversy. This enzyme is 
involved in the conversion of dopachrome to eumelanin, and 
was named successively L-dopachrome conversion factor [ 31, 
L-dopachrome oxidoreductase [4] and L-dopachrome iso- 
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merase [5]. The enzyme has finally been renamed dopa- 
chrome tautomerase, a name that describes more precisely 
the reactions involved [6]. Dopachrome tautomerase trans- 
forms dopachrome into 5,6-dihydroxyindole-2-carboxylic 
acid. In the absence of dopachrome tautomerase or divalent 
cations, dopachrome spontaneously converts to dihydroxy- 
indole. The synthesis of dihydroxyindole-carboxylic acid 
versus dihydroxyindole influences the later steps in melano- 
genesis since it has been reported that dihydroxyindole-car- 
boxylic-acid-derived melanins and dihydroxyindole-derived 
melanins differ in several properties, such as their solubility, 
flocculence and color [7, 81. 
A mouse cDNA clone for tyrosinase-related-protein-2 has 
recently been shown to encode a protein with dopachrome- 
tautomerase activity [9], and maps to the slaty locus on 
mouse chromosome 14. Moreover, an amino acid substitu- 
tion (Arg194 to Gln) present in slaty mice is responsible for a 
significant decrease in dopachrome-tautomerase activity [9]. 
There has been no previous study describing the isolation of 
a human dopachrome-tautomerase protein or the correspond- 
ing gene. However, an antibody produced against the C-ter- 
minus of the murine tyrosinase-related-protein-2 reacts with 
human melanocytic cells [lo], suggesting the existence of a 
human homologue of tyrosinase-related-protein-2/dopa- 
chrome tautomerase. In this study, we report the isolation 
of a full-length cDNA clone for human tyrosinase-related- 
protein-2/dopachrome tautomerase, and demonstrate its ex- 
pression in melanocytic cells, as well as its chromosomal 
localization. Additionally, we show that only the melanocytic 
cells which express the tyrosinase-related-protein-2 transcript 
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demonstrate dopachrome-tautomerase activity, strongly sug- 
gesting that this gene encodes dopachrome tautomerase. 
MATERIALS AND METHODS 
Cells 
Human melanoma cell lines SK-MEL-19, SK-MEL-131 
(clones 1-5 and 344), SK-MEL 188, and the murine mela- 
noma cell line B16 have been previously described [ I l l  and 
were maintained in minimum essential medium supple- 
mented with 10% fetal calf serum. The human melanoma 
cell lines BEU, LND1, IGR3, SCL, HBL and the murine 
melanoma cell line Cloudman S91, were cultivated in HAM 
F10 medium supplemented with 5% fetal calf serum. AZM, 
MNGHM, MNWC, MNKB were normal human melanocytes 
cultured in HAM F10 medium as described by Smit et al. 
[12]. The cell line BEU was the generous gift of Dr J. F. 
DorC (Institut National de la SantC et de la Recherche Mkdi- 
cale, Lyon) and IGR3 was kindly provided by Dr Aubert 
(Marseille). The cell line Cloudman S91 was a gift from Dr 
Abdel-Malek (Cincinnati, Ohio). SCCl is a human lingual 
carcinoma cell line. 
Isolation of human tyrosinase-related-protein-2 cDNA 
Degenerate polymerase-chain-reaction (PCR) primers 
corresponding to homologous regions in the members of the 
tyrosinase-related-protein family (murine and human), were 
synthesized. These included the forward primer 
T T C  A 
C C A  G 
5' GCACTCGAGA-GA- -GIGA-IINTGGCC 3', 
and the reverse primer 
T G  G 
G A  A 
5' TAGGAGCTC- -TT-TGICCIATNGGNGC 3'. 
These primers correspond to amino acids DDREXWP 
(forward primer, flanked by an XhoI site) and APIGHNR 
(reverse primer, flanked by a SstI site) in the different tyrosi- 
nase-related proteins. Total RNA was prepared from mela- 
noma cells and first-strand cDNA was synthesized as de- 
scribed by reverse transcription [13]. 1 p1 of the total 50-yl 
reverse-transcription reaction was subjected to amplification 
by PCR. Thirty cycles (94"C, 1 min; 45"C, 2 min; 74"C, 
2 min) were performed in a Hybaid thermocycler. The 
amplification products were digested with PvuII (which has 
one cleavage site in the tyrosinase and tyrosinase-related- 
protein-1 cDNAs) and the products were electrophoresed on 
0.8% agarose gels or on 5 %  non-denaturing polyacrylamide 
gels. DNA fragments were transferred to nylon membranes 
and hybridized with probes specific for human tyrosinase and 
tyrosinase-related-protein-1 . Specific bands which did not 
hybridize were gel purified, labeled with [a-"P]dCTP using 
the random-priming method 1141, and used to screen a cDNA 
library constructed from the melanoma cell line SK-MEL-19 
1151. Positive clones were analyzed and sequenced on both 
strands as previously described [ 151. 
Northern-blot analysis 
Total RNA was extracted and 10 pg was fractionated on 
1 % formaldehyde/agarose gels, and transferred onto Gene- 
screen membranes (Dupont). cDNA probes were labeled 
using the technique of random priming (USB) and the radio- 
label [a-3ZP]dCTP. 
Determination of dopachrome-tautomerase activity 
Prior to determination of dopachrome-tautomerase en- 
zyme activity, cells (8.5X106/ml) were lysed in Hanks' bal- 
anced salt solution containing l %  Nonidet P40. 0.1 mM 
EDTA was added to prevent dihydroxyindole-carboxylic- 
acid formation due to metal ions [16]. After homogenization 
and sonication, cellular debris were eliminated by a 10-min 
centrifugation at 9000 g. Resulting lysates were immediately 
assayed by spectrophotometry using two different parame- 
ters. The absorbance decrease at 475 nm, due to L-dopa- 
chrome consumption, and the parallel absorbance increase 
at 308 nm, due to dihydroxyindole-carboxylic-acid formation 
were both followed. In both cases, dopachrome was prepared 
by the stoichiometric oxidation of L-Dopa by sodium perio- 
date. 1 U of dopachrome tautomerase was defined as the 
amount of enzyme that produces 1 pmol of dihydroxyindole- 
carboxylic acid/min at 25 "C [ 171. Tyrosinase activity was 
determined using a modification [18] of the Pomerantz meth- 
od 1191, using ~-[3,5-'H]tyrosine as substrate. 1 U of tyro- 
sine-hydroxylase activity was defined as the amount of en- 
zyme that catalyzes the hydroxylation of 1 pmol L-tyrosine/ 
min at 37 "C. Protein concentrations were determined using 
the Lowry assay [20]. The eumelanin content has been pre- 
viously determined for the cell lines IGR3, LNDl, HBL and 
SCL 1211 ; for the other cell lines, pigmentation was visually 
estimated by the intensity of the individual brown or black 
pellets. 
Fluorescence in-situ hybridization 
The tyrosinase-related-protein-2 cDNA insert of the 
clone 5B2 was used as a probe for in-situ hybridization. Af- 
ter labeling by nick translation with 5-(N-[biotinyl-~-amino- 
caproyl]-3-aminoallyl)-2'-deoxyuridine 5'-triphosphate (Bio- 
11-dUTP), the probe was purified over a Sephadex (3-50 col- 
umn. The biotinylated probe (100 ng/ml) was added to the 
hybridization mixture (50% formamide, 2 X NaCUCit, 10% 
dextran sulfate, pH 7, 500 ng/ml sonicated salmon sperm 
DNA; 20X NaCl/Cit = 3 M NaC1, 0.3 M sodium citrate, 
pH 7), denatured and hybridized on the slide as described 
[22]. After an overnight incubation and post-hybridization 
washes, the biotinylated probe was detected by avidin-fluo- 
rescein isothiocyanate and the signal was amplified with ad- 
ditional treatments of biotinylated goat anti-avidin and avi- 
din-fluorescein isothiocyanate. For the chromosomal local- 
ization, fluorescent R bands were obtained as described [23]. 
RESULTS 
A third member of the human tyrosinase-related-protein 
family is detected by PCR 
PCR primers were designed based on conserved protein 
sequences between the different tyrosinase-related proteins 
and tyrosinase. Using these primers, cDNAs were amplified 
from several human melanoma cell lines (SK-MEL 188, SK- 
MEL-19 and LNDl), and in each case a single, well-defined 
1-kb product was observed (data not shown). Human tyrosi- 
nase and tyrosinase-related-protein-1 each contain unique 
PvuII sites (at Ala299 in tyrosinase and at Ala292 in tyrosi- 
nase-related-protein-l), thus allowing for their discrimina- 
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M Ty Ttp-1 PCR 
Fig. 1. Restriction digest of PCR products from members of the 
tyrosinase-related-protein family. PCR products from tyrosinase 
(Ty), tyrosinase-related-protein 1 (Trp-1 ) and the degenerate-primer 
(PCR) reactions were digested using PvuII. The degenerate-primer 
reactions generated two additional fragments which are not found in 
the tyrosinase-specific and TRP-1-specific reactions. Arrows indi- 
cate the specific TRP-2 amplified products. M, molecular markers 
(4x174 DNA digested with HueIII) of 1353, 1078, 872, 603, 
310 bp, respectively. 
tion. However, restriction of the PCR reaction products with 
PvclII revealed the presence of a third amplified sequence, in 
addition to the expected products from tyrosinase and tyrosi- 
nase-related-protein-1. This third sequence also contained a 
PvuII site, and generated two fragments of 536 bp and 
422 bp (Fig. 1). No additional fragments were observed, sug- 
gesting that there are no more than three members of the 
human tyrosinase-related gene family which can be ampli- 
fied under these conditions. 
with human tyrosinase-related-protein-1 and human tyrosi- 
nase were 46% and 40%, respectively (Fig. 3). 
Expression of the human tyrosinase-related-protein-2 
transcript 
Tyrosinase-related-protein-2 expression was analysed 
using a panel of human melanocytic cells by Northem-blot 
analysis. In Fig. 4A, the specific transcript for tyrosinase- 
related-protein-2 is demonstrated at approximately 4.5 kb. 
This contrasts with the size of the murine transcript which is 
detected at approximately 3.0 kb (Fig. 4, lane 8). The differ- 
ence in size between the transcript detected in Northern-blot 
analysis and the isolated cDNA for the human tyrosinase- 
related-protein-2 may indicate the presence of an extended 3’ 
untranslated region in the gene. Melanocytic cell lines can 
be placed into three groups based on the levels of tyrosinase- 
related-protein-2 transcripts. No transcripts were detected in 
the cell lines IGR3 (Fig. 4) and SK-MEL-131 (clone 1-5) 
(data not shown). A second group of cells showed low or 
moderate expression of TRP-2 transcripts [cell lines SCL, 
HBL and cell line BEU and normal melanocytes (AZM, 
MNGHM, MNWC, MNKB, data not shown)]. The third 
group [SK-MEL-19, SK-MEL-188, SK-MEL-131 (clone 
344), Fig. 4 and LND1, data not shown] show relatively high 
levels of expression. No transcripts were detected in RNA 
from the human carcinoma cell line SCCl (Fig. 4) or from 
human fibroblasts (data not shown). These data were also 
confirmed by PCR amplification of cDNA from these cell 
lines (data not shown). Fig.4B shows the hybridization 
pattern with the actin control cDNA demonstrating equiva- 
lent RNA loading in each lane. 
Isolation and characterization of a cDNA encoding 
human tyrosinase-related-protein 2 
Dopachrome-tautomerase activity detected 
in human melanocytic cells in vitro 
A cDNA library from the human melanotic cell line SK- 
MEL-19 was screened using the 536-bp-specific fragment 
described above. Nine positive clones were isolated and each 
possessed the same restriction map, differing only in their 
overall lengths. The complete nucleotide sequence of the 
longest of these clones, termed 5B2, showed a single open 
reading frame encoding a 5 19-amino-acid polypeptide 
(Fig. 2). A leader sequence (residues -21 to -1) was as- 
signed based on the rule of von Heijne [24]. Using the hydro- 
phobicity pattern [25], a transmembrane domain could be 
predicted (residues 453 -474). The 15 cysteine residues pre- 
sent in the mouse tyrosinase-related-protein-2 and in the 
other tyrosinase-related proteins [26] were conserved, and 
seven potential glycosylation sites could be predicted (NXS 
or NXT), in positions identical with the mouse tyrosinase- 
related-protein-2. Significantly, the cysteine residues at posi- 
tions 85 and 88, which are potentially involved as iron-bind- 
ing sites [27] are conserved in the murine tyrosinase-related- 
protein-2. Histidine residues, presumably involved in copper 
binding are also conserved. Sequence analysis and compari- 
son with the mouse tyrosinase-related-protein-2 cDNA re- 
vealed similarity at the nucleotide (70%) and at the amino 
acid level (80%). Interestingly, a group of amino acids in the 
mouse sequence which contains the site of the slaty mutation 
(HYYSVRDLLL, codon 173) was conserved in the human 
tyrosinase-related-protein-2. Based on these similarities, we 
designated the clone 5B2 as the human homologue for tyro- 
sinase-related-protein-2. Amino acid sequence similarities 
We have further analysed the relationship between the 
presence of tyrosinase-related-protein-2 transcripts and dopa- 
chrome-tautomerase activity. In these studies, the murine 
melanoma cell-line Cloudman S91 was used as a positive 
control. The dopachrome-tautomerase activity is presented as 
the increase of absorbance at 308 nm, which is a direct mea- 
sure of the appearance of dihydroxy-indole-carboxylic acid. 
As shown in Table 1, activity can be detected in all the cells 
expressing the 4.5-kb transcript for tyrosinase-related-pro- 
tein-2. Of particular significance is the high level of activity 
detected in SK-MEL-19 cells. However, there was not al- 
ways a direct correlation between the level of dopachrome- 
tautomerase activity and the expression of the specific tran- 
scripts (for example, compare SK-MEL-188 and SK-MEL- 
19). Tyrosine-hydroxylase activity was additionally mea- 
sured in this panel of cells and its activity did not correlate 
with that of dopachrome tautomerase. Moreover, there was 
no direct relationship between the presence of eumelanin and 
the dopachrome-tautomerase activity detected in these cells. 
Chromosomal mapping by in-situ hybridization 
Localization of the human tyrosinase-related-protein-2 
gene (termed TYRP2 in accordance with the human nomen- 
clature rules) was performed using non-radioactive hybrid- 
ization with the 5B2 cDNA insert. Of the 40 metaphases 
examined, 26 (65 %) demonstrated a specific signal, defined 
by two symmetrical yellow-green spots on both chromatids 
130 
GGACTGGGTGCTCTGTAAATTAACTCAATTAGACAAAGCC~CTTAACGGGGGAAGATGGT~~GCG~ACCC~ATT~T~GGTT 
GTTAGAGGCGCTTCTMGTAAGTCTGTTAGTTGTTTGAATCACAT~TTGTGCCffiCACGTTCATGTACACATGTGCACACATG 
T A A C C T C T G T G A T T C T T G T G G G T A T T T T T T T A A G A A G A A A G G A A T A ~ C A A A ~ T ~ T A C T G ~ G ~ G A C T G A A A G  
AGTAGAAGATAAGGAG~GTACGACAGAGA~GGAAAGTAAGAGAGAGAGAGAGCTCTCCCAATTATAAAGCC ATG AGC CCC 
M S P -19 
-1 4 1  
CTT TGG TGG GGG TTT CTG CTC AGT TGC TTG GGC TGC AAA ATC CTG CCA GGA GCC CAG GGT CAG TTC CCC 
L W W G F L L S C L G C K I L P G A Q G Q F P  5 
C ATG ACG GTG GAC AGC CTA GTG AAC AAG GAG GC GC CCA CGC CTG GGT GCA GAG TCG GCC 
i G A $ T c B M  T V D S L V N K E a h P  R L G A E S A 23 
AAT GTC TGT GGC TCT CAG CAR GGC CGG GGG CAG TGC ACA GAG GTG CGA GCC GAC ACA AGG CCC TGG AGT 
N V O G S Q Q G R G Q O T E V R A D T R P W S  51 
GGT CCC TAC ATC CTA CGA AAC CAG GAT GAC CGT GAG CTG TGG CCA AGA A M  TTC TTC CAC CGG ACC GC 
G P  Y I  L R N Q D D R E L W P  R K F F H R T a  74 
AAG TGC ACA GGA M C  TTT GCC GGC TAT AAT TGT GGA GAC TGC AAG TTT GGC TGG ACC GGT CCC M C  TGC 
K @ T G N F A G Y N @ G D @ K F G W T G P N @  97 
GAG CGG AAG AAA CCA CCA GTG ATT CGG CAG AAC ATC CAT TCC TTG AGT CCT CAG GAA AGA GAG CAG TTC 
E R K K P ~ V I R Q N I H S L S P Q E R E Q F  120 
TTG GGC GCC TTA GAT CTC GCG AAG AAG AGA GTA CAC CCC GAC TAC GTG ATC ACC ACA CAR CAC TGG CTG 
L G A L D L A K K R V H P D Y V I T T Q H W L  143 
GGC CTG CTT GGG CCC AAT GGA ACC CAG CCG CAG TTT GCC AAC TGC AGT GTT TAT GAT TTT TTT GTG TGG 
G L L G P N G T Q P Q F A N C S V Y D F F V W  166 
CTC CAT TAT TAT TCT GTT AGA GAT ACA TTA TTA GGA CCA GGA CGC CCC TAC AGG GCC ATA GAT TTC TCA 
L H Y Y S V R D T L L G P G R P Y R A I D F  S 189 
CAT CAA GGA CCT GCA TTT GTT ACC TGG CAC CGG TAC CAT TTG TTG TGT CTG GAA AGA GAT CTC CAG CGA 
H Q G P A F V T W H R Y H L L C L E R D L Q R  212 
CTC ATT GGC AAT GAG TCT TTT GCT TTG CCC TAC TGG AAC TTT GCC ACT GGG AGG AAC GAG TGT GAT GTG 
L I G N E S F A L P Y W N F A T G R N E O D V  235 
6 T D Q L F G A A R P D D P T L I S R N S R F  258 
TCC AGC TGG GAA ACT GTC TGT GAT AGC TTG GAT GAC TAC AAC CAC CTG GTC ACC TTG TGC AAT GGA ACC 
S S W E T V @ D S L D D Y N H L V T L @ N G T  281 
TAT GAA GGT TTG CTG AGA AGA AAT CAA ATG GGA AGA AAC AGC ATG AAA TTG CCA ACC TTA AAA GAC ATA 
Y E G L L R R N Q M G R N S M K L P T L K D I  304 
CGA GAT TGC CTG TCT CTC CAG AAG TTT GAC AAT CCT CCC TTC TTC CAG AAC TCT ACC TTC AGT TTC AGG 
R D O L S L Q K F D N P P F F Q N S T F S F R  327 
AAT GCT TTG GAA GGG TTT GAT AAA GCA GAT GGG ACT CTG GAT TCT CAA GTG ATG AGC CTT CAT AAT TTG 
N A L E G F D K A D G T L D S Q V M S L H N L  350 
GTT CAT TCC TTC CTG AAC GGG ACA AAC GCT TTG CCA CAT TCA GCC GCC AAT GAT CCC ATT TTT GTG GTT 
V H S F L N G T N A L P H S A A N D P I F V V  373 
CTT CAT TCC TTT ACT GAT GCC ATC TTT GAT GAG TGG ATG AAA AGA TTT AAT CCT CCT GCA GAT GCC TGG 
L H S F T D A I F D E W M K R F N P P A D A W  396 
CCT CAG GAG CTG GCC CCT ATT GGT CAC AAT CGG ATG TAC ARC ATG GTT CCT TTC TTT CCT CCA GTG ACT 
P Q E L A P I G H N R M Y N M V P F F P P V T  419 
GT ACA GAC CAG CTG TTT GGG GCA GCG AGA CCA GAC GAT CCG ACT CTG ATT AGT CGG AAC TCA AGA TTC 
AAT GAA GAA CTC TTT TTA ACC TCA GAC CAA CTT GGC TAC AGC TAT GCC ATC GAT CTG CCA GTT TCA GTT 
N E E L F L T S D Q L G Y S Y A I D L P V S V  442 
GAA GAA ACT CCA GGT TGG CCC ACA ACT CTC TTA GTA GTC ATG GGA ACA CTG GTG GCT TTG GTT GGT CTT 
E E T P G W P T T L L V V M G T L V A L V G T -  4 65 
TTT GTG CTG TTG GCT TTT CTT CAA TAT AGA AGA CTT CGA AAA GGA TAT ACA CCC CTA ATG GAG ACA CAT 
F V L L A F L O Y R R L R K G Y T P L M E T H  488 
TTA AGC AGC AAG AGA TAC ACA GAA GAh GCC TAG GGTGCTCATGCCTTACCTAAGAG?+AGAGGCTGGCCAAGCCACAGTTC 
L S S K R Y T E E A  4 98 
TGACGCTGACAATAAAGGAACTAATCCTCACTGTTCCTTCTTGAGT~GATCTTTGACTTAGGTTCTTCTATAGTGATGA~TACTCA 
TTCAGAAGA 
Fig. 2. The complete nucleotide and derived amino acid sequence of the cDNA clone 5B2. Residues of the signal sequence are indicated 
by negative numbers and the predicted cleavage site is indicated by an arrow. Cysteine residues are circled and the putative transmembrane 
domain is underlined. 
on the long arm of one chromosome, and 18 (45%) exhibited 
the double spots on two identical chromosomes (Fig. 5A). 
Double signals were not detected on any other chromosomal 
region. R-banding patterns allowed for the precise definition 
of the hybridization signals on chromosome 13 at 13q32 
(Fig. 5B). This localization extends the region of conserved 
synteny between human chromosome 13 and mouse chromo- 
some 14. A group of genes including Es-10, Htr2 and Rb 
map close together on mouse chromosome 14, about 25 cM 
proximal to Tyrp2 (Fig. 6). The corresponding human genes 
for Es-10, Htr2, and Rb localize to 13q14.1-14.2, proximal 
to the gene for TYRP2. Cxn26/CXN26, which maps proxi- 
mal to Htr2lRb in the mouse, has not been assigned to a 
specific band on human chromosome 13. However, based on 
the conservation presented in this study, we would predict 
that CXN26 will map proximal to 13q14. 
131 
hTRPI  : 
hTRP2: 
hTYR : 
hTRP1: 
hTRP2: 
hTYR : 
hTRPI  : 
hTRP2: 
hTYR : 
hTRPl  : 
hTRP2: 
hTYR : 
hTRPI : 
hTRP2: 
hTYR : 
hTRP1: 
hTRP2: 
hTYR : 
hTRP1: 
hTRP2: 
hTYR : 
hTRP1: 
hTRPP: 
hTYR : 
hTRPI  : 
hTRP2: 
hTYR : 
* ** 
MSAPKLLSLGCIFFPLLLFQQARAPFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSS 
MSPLWWGFLLSCLGCKILPG-AQGQFPRVCMTVDSLVNKECCPRLGAESA---NVCGSQQ 
MLLAVLYCLLWSFQT------SAGHFPRACVSSKNLMEKECCPPWSGDRSP-~--CGQLS 
I, * *  * *  __._._ 
GRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGA 
GRGQCTEVRADTRPWSGPYILRNQDDRELWPRKFFHRTCKCTGNFAGYNCGDCKFGWTGP 
GRGSCQNILLSNAPLGPQFPFTGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFWGP 
ACDQRVL-IVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGP-DGNTPQ 
NCERKKPPVIRQNIHSLSPQEREQFLGALDLAKKRVHPDYVITTQHWLGLLGP-NGTQPQ 
NCTERRL-LVRRNIFDLSAPEKDKFFAYLTLAKHTISSDYVIPIGTYGQMK---NGSTPM 
FENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFL~HRYHLLRLEKDMQEM 
FANCSVYDFFVWLHYYSVRDTLLGPGR-PYRAIDFSHQGPAFVNVHRYHLLCLERDLQRL 
FNDINIYDLFVWMHYYVSMDALLGGYE-IWRDIDFAHEAPAFLPWHRLFLLRWEQEIQKL 
* *  
LQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDT 
IGNESFALPYWNFATGRNECDVCTDQLFGAARPDDPTLISRNSRFSSWETVCDSLDDYNH 
TGDENFTIPYWDWRDA-EKCDICTDEYMGGQHPTNPNLLSPASFFSSWQIVCSRLEEYNS 
LGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNT 
LVTLCNGTYEGLLRRNQMGRNSM----KLPTLKDIRDCLSLQKFDNPPFFQNSTFSFRNA 
HQSLCNGTPEGPLRRNPGNHDKSRTP-RLPSSADVEFCLSLTQYESGSMDKAANFSFRNT 
VEKYSDP-TGLYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRR 
LEGFD)(A-DGTLDSQVMSLHNLVHSFLNGTNALPHSAANDPIFVVLHSFTDAIFDEWMKR 
LEGFASPLTGIADASQSSMHNALHIYMNGTMSQVQGSANDPIFLLHHAFVDSIFEQWLRR 
< - - -  - _ _  
YNADISTFPLENAPfGHNRQYNMVPMlPPVTNTEMFVTAPDNLGYTYEIQWP-SREFSVP 
FNPPADAWPQELAPIGHNRMYNMVPFFPPVTNEELFLTSDQ-LGYSYAIDLPVSVEETPG 
HRPLQEVYPEANAPIGHNRESYMVPFIPLYRNGDFFISSKD-LGYDYSYLQD-SDPDSFQ 
EIIAIAVVGALLLVALIFGTASYLIRARRSMDEANQPLLTDQYQCYAEERI 
WPTTLLVVMGTLVALVG~FVLCAFLQY RRLRKGYTPCMETHLSSKRYTEEA 
DYIKSYLEWSRIWSWLLGAAMVGAVLTALLAGLVSLLCRHKRKQLPEEKQPLLMEKEDYHSLYQSHL 
Fig. 3. Amino acid sequence alignment between the members of the human tyrosinase-related family. Cysteine residues are indicated 
(*) and the regions corresponding to the degenerate PCR primers are indicated by horizontal arrows. 
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Fig. 4. Northern-blot analysis of total RNA from a panel of cells. 
1Opg RNA was loaded in each lane. Lane 1, human carcinoma 
SCCl ; lane 2, IGR3; lane 3, HBL; lane 4, SCL; lane 5, SK-MEL- 
131 (clone 344), lane 6, SK-MEL-188; lane 7, SK-MEL 19; lane 8, 
murine melanoma B16. (A) The blot was hybridized with the [a- 
'ZP]dCTP-labeled insert of clone 5B2. (B) The blot was hybridized 
with the actin control probe. In each case, the arrows indicate the 
specific transcripts. 
In this study, we describe the isolation of a human cDNA 
clone encoding dopachrome tautomerase, mapping to chro- 
mosome region 13q32 and thus likely to be the homologue 
of the mouse tyrosinase-related-protein-2/dopachrome-tauto- 
merase gene [9]. Previous studies had suggested the exis- 
tence of a human protein cross-reacting with an antisera 
against murine dopachrome tautomerase [lo] and the pres- 
ence of a similar activity in human hair bulb [4]. This study 
indicates the existence of the enzyme dopachrome tauto- 
merase in human cells. 
The human tyrosinase-related-protein-2 cDNA isolated in 
this study encompasses the complete coding sequence of the 
protein. It demonstrates high similarity with its mouse coun- 
terpart at both the nucleotide and the amino acid level. It 
is interesting to note that despite this similarity, the mouse 
tyrosinase-related-protein-2 cDNA does not detect its human 
equivalent by Northern-blot analysis (unpublished results), 
although the human probe cross-reacts with the murine tran- 
script. The sequence that we report in this study provides 
additional elements for the understanding of the evolution of 
this gene family. Each of the 15 cysteine residues present in 
the other tyrosinase-related proteins are conserved, as well 
as the histidine residues putatively involved in copper bind- 
ing, and therefore in the biological activity of the enzyme. 
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Table 1. Summary of melanogenic properties of analyzed cell lines. Levels of TRP-2 transcripts were based on Northem-blot analysis 
(Fig. 4 and data not shown). -, no transcripts detected; +, moderate-level expression; + +, + + +, high-level expression. Pigmentation 
refers to the content of eumelanin, which was estimated visually for all cell lines. In addition, the eumelanin content for BEU, LND1, HBL 
and SCL have been determined (AHP/PTCA levels [21]). TH, tyrosine hydroxylase; DCT, dopachrome tautomerase; n.d., not determined. 
Cell line TH activity DCT activity TRP-2 transcript level Pigmentation level 
SCCl 
IGR3 
BEU 
LNDl 
HBL 
SCL 
SK MEL 131 (clone 344) 
SK MEL 19 
SK MEL 188 
S91 
0 
0 
857.0 5 402.0 
621.6 5 258.0 
694.4 5 131.0 
354.8 5 2.1 
n.d. 
895.2 5 337.0 
519.7 5 63.0 
19.4 ? 9.4 
0 
0 
3.8 2 0 . 7  
9.2 5 3.4 
0 
3.9 2 1.2 
0 
29.1 2 5.9 
1.9 5 0.3 
20.8 5 9.2 
- 
+ 
+++ 
+ + 
++ 
+++ 
++ 
n.d. 
+ 
++ 
+ 
+++ 
+++ 
Fig. 5. Chromosomal localization of TYRP2 by non radioactive in-situ hybridization on human chromosomes. (A) Double spots are 
observed on the two chromosomes 13 at band 13q32. (B) R-banding pattern of the same metaphase. 
Dopachrome tautomerase is also dependent on the presence 
of iron for optimum biological activity [27], and it is impor- 
tant to note the conservation of the cysteine residues poten- 
tially involved in iron binding. Other conserved regions of 
the molecule, such as the transmembrane domain, emphasize 
the probable importance of these regions in the function of 
tyrosinase-related proteins. In slaty mice, the amino acid 
Arg194 in the murine tyrosinase-related-protein-2 is substi- 
tuted by a glutamine residue. The wild-type codon is only 
moderately conserved between the other tyrosinase-related 
proteins. However, it remains identical between the mouse 
and human sequences, suggesting that this site could play a 
role in the function of dopachrome tautomerase [9]. In addi- 
tion, the C-terminus recognized by the serum anti-PEP-8 [lo] 
is also well conserved, with only one amino acid difference 
(at position 488), replacing a glycine residue by a histidine. 
This similarity should allow the use of the anti-PEP-8 serum 
for biochemical characterization of the human tyrosinase-re- 
lated-protein-2, including the analysis of its post-translational 
modifications, levels of glycosylation and intracellular pro- 
cessing. 
In a previous study, we had shown that tyrosinase activity 
is not always correlated with the expression of the corre- 
sponding transcript and the amount of visible melanin pro- 
duced in melanocytic cells [15]. In contrast, levels of tyrosi- 
nase-related-protein-1 mRNA and protein are directly corre- 
lated with the eumelanin content found in melanocytic cells 
[21, 281. In light of these observations, it is interesting to 
note that although the presence of the tyrosinase-related-pro- 
tein-2 transcript coincides with the detection of the dopa- 
chrome-tautomerase activity, there are individual variations 
in the levels of the enzyme activity when compared to those 
of the transcript in different cell lines. These data suggest the 
existence of possible post-transcriptional regulatory mecha- 
nisms, similar to those which have been reported for the tyro- 
sinase transcript [28]. It should also be noted that no direct 
correlation exists between the expression of tyrosinase-relat- 
ed-protein-2 and the presence of visible melanin andlor activ- 
ity of tyrosinase. These data differ from those recently re- 
ported by Kameyama et al. [29]. However, in their experi- 
ments, the authors used another approach including the use 
of clones derived from one cell line which could explain the 
discrepancies with our data. 
Several studies have reported that melanocyte-stimulat- 
ing hormone regulates dopachrome-tautomerase activity, al- 
though there are conflicting data concerning the precise ef- 
fects that this hormone has on in-vivo transformation of do- 
pachrome [4,29,301, in contrast to those reported for mouse 
tyrosinase activity [31]. Differential regulatory effects of 
melanocyte-stimulating hormone and other melanogenic 
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Fig. 6. Synteny between human chromosome 13 and mouse chro- 
mosome 14. Established syntenic markers are indicated by a solid 
connecting line. Potential homologous regions are shown by a dotted 
line. 
agents, such as theophylline, dibutyryl CAMP, and isobutyl 
methylxanthine would argue for specific mechanisms regu- 
lating the expression of the different tyrosinase-related pro- 
teins. This hypothesis is further substantiated by major differ- 
ences in the gene structure and regulatory elements of tyrosi- 
nase and tyrosinase-related-protein-1 [28, 32, 331. The struc- 
tural organization of the mouse and human tyrosinase-relat- 
ed-protein-2 loci remain to be elucidated, as well as the regu- 
latory elements which control their expression. Steel et al. 
[34] have shown that the tyrosinase-related-protein-2 gene is 
the first member of the tyrosinase-related-protein family to 
be expressed in the developing mouse embryo, suggesting a 
hierarchy of the transcriptional control of the tyrosinase-re- 
lated-protein genes. 
The availability of a cDNA clone for human tyrosinase- 
related-protein-2 will help to resolve questions regarding the 
biological activity of dopachrome tautomerase and its modu- 
lation by melanogenic agents. Indeed, transfection of our 
cDNA and characterization of the activity present in transfec- 
tants, coupled with the use of specific antibodies, such as 
PEP-8, would provide direct evidence of the identity of the 
human protein encoded by the gene reported in this study. 
Transfection experiments performed with a full-length tyrosi- 
nase-related-protein-2 cDNA will also permit the analysis of 
potential interactions between tyrosinase, tyrosinase-related- 
protein 1 and tyrosinase-related-protein-2. It has been re- 
ported that these three melanogenic proteins exist as a high- 
molecular-mass complex in vivo inside the melanosome 1351. 
It will be of particular interest to investigate the type of mela- 
nin produced in the presence (or absence) of the different 
genes. This kind of experimental model can be designed in 
an elegant manner with the use of transfectants, using the 
corresponding cDNAs. 
Mouse mutations described at the pigmentation loci have 
provided invaluable information regarding their respective 
functions in melanogenesis. Complementary biochemical 
studies performed with specific antibodies have helped in the 
analysis of the tyrosinase-related-proteins biochemical struc- 
ture and can be used as a direct measure of their in-vitro 
activity. It remains to be seen whether these melanogenic 
proteins require co-translation and specific interactions for 
efficient melanin synthesis. In this respect, transfection ex- 
periments are likely to represent an interesting in-vivo model, 
particularly for studying the functions and interactions of the 
melanogenic proteins, the pathway to melanosome biogene- 
sis and the transport of the pigment vesicles to surrounding 
keratinocytes. 
We would like to thank Dr Francisco Solano for advice about 
the dopachrome-tautomerase assays and helpful discussions, and Dr 
James P. Di Santo for critically reading the manuscript. This work 
was supported by grants from the Institut National de la Santk et de 
la Recherche Mkdicule (B. B, L. D. and D. C.), and from the Fonda- 
tion R et 7: Lefebvre (V. d. M.). I. J. J. was a Lister fellow. 
REFERENCES 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
Korner, A. M. & Pawelek, J. M. (1982) Science 217, 1163- 
Silvers, W. K. (1979) in The coat colors of mice, pp. 1-30, 
Pawelek, J. M., Komer, A., Bergstrom, A. & Bologna, J. (1980) 
Barber, J. I . ,  Townsend, D. W., Olds, D. P. & King, R. A. (1984) 
Pawelek, J. M. (1990) Biochem. Biophys. Res. Commun. 166, 
Aroca, P., Garcia-Borron, J. C., Solano, F. & Lozano, J. A. 
Orlow, S. J., Osber, M. P. & Pawelek, J .  M.(1992) Pigment Cell 
Pawelek, J. M. (1991) Pigment Cell Res. 4, 53-62. 
Jackson, I. J., Chambers, D. M., Tsukamoto, K., Copeland, N. 
G., Gilbert, D. J., Jenkins, N. A. & Hearing, V. J. (1992) 
Tsukamoto, K., Jackson, I. J., Urabe, K., Montague, P. M. & 
Hearing, V. J. (1992) EMBO J .  11, 519-526. 
Houghton, A. N., Eisinger, M., Albino, A. P., Cairncross, J. 
G. & Old L. 0. (1982) J. Exp. Med. 156, 1755-1765. 
Smit, N., Westerhof, W., Asghar, S. & Pavel, S. (1989) J. Invest. 
Dermatol. 85, 169- 174. 
Feinberg, A. P. & Vogelstein, B. (1984) Anal. Biochem. 137, 
266-270. 
Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989) Molecular 
cloning: a laboratory manual, 2nd edn, Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY. 
Bouchard, B., Fuller, B. F., Vijayasaradhi, S. & Houghton, A. 
N. (1989) J.  Exp. Med. 169, 2029-2042. 
Palumbo, A., Solano, F., Misuraca, G., Aroca, P., Garcia-Bor- 
ron, J. C., Lozano, J. A. & Prota, G. (1991) Biochim. Biophyv. 
Acta 115, 1-5. 
Aroca, P., Solano, F., Garcia-Borron, J .  C. & Lozano, J. A. 
(1990) J. Biochem. Biophys. Methods 21, 35-46. 
Jara, J. R., Solano, F. & Lozano, J. A. (1988) Pigment Cell Res. 
Pomerantz, S .  H. (1969) Science 164, 838-842. 
Lowry, 0. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. 
(1951) J. Biol. Chem. 193, 265-275. 
del Marmol, V., Ito, S., Jackson, I. J., Vachtenheim, J., Berr, P., 
Ghanem, G., Morandini, R., Wakamatsu, K. & Huez, G. 
(1993) FEBS Lett., in the press. 
Cherif, D., Bernard, 0. & Berger, R. (1989) Hum. Genet. 81, 
358-362. 
Cherif, D., Julier, C., Delattre, O., DerrC, J., Lathrop, G. M. & 
Berger, R. (1990) Proc. NatlAcad. Sci. USA 87, 6639-6643. 
von Heijne, G. (1986) Nucleic Acids Res. 14, 4683-4690. 
Kyte, J. & Doolitle R. (1982) J. Mol. Biol. 157, 105-110. 
Hearing, V. H. & Jimenez, M. (1989) Pigment Cell Res. 2, 75- 
1165. 
Springer Verlag, Basel. 
Nature 286, 617-619. 
J. Invest. Dermatol. 83, 145 - 149. 
1328-1333. 
(1990) Biochim. Biophys. Acta 1035, 266-275. 
Res. 5, 113-121. 
EMBO J .  11, 527-535. 
I, 332-339. 
85. 
134 
27. Chakraborty, A. K., Orlow, S. J. & Pawelek, J. M. (1992) FEBS 
Lett. 302, 126-128. 
28. Bouchard, B., Murty, V. V. V. S., Vijayasaradhi, S. & Houghton, 
A. N. (1992) J. Invest. Dermatol. 98, 824. 
29. Kameyama, K., Takemura, T., Hamada, Y., Sakai, C., Kondoh, 
S., Nishiyama, S., Urabe, K. & Hearing, V. J. (1993) J. Invest. 
Dermatol. 100, 126-131. 
30. Martinez-Liartre, J. H., Solano, F., Garcia-Borron, J. C., Jara, J. 
R. & Lozano, J. A. (1992) J. Invest. Dermatol. 99, 435-439. 
31. Jimenez, M., Kameyama, K., Maloy, W. L., Tomita, Y. & Hear- 
ing, V. J. (1989) Proc. Natl Acad. Sci. USA 85, 3830-3834. 
32. Jackson, I. J., Chambers, D. M., Budd, P. S.  & Johnson, 
33. Shibata, K., Takeda, K., Tomita, Y., Tagami, H. & Shibahara, 
34. Steel, K. P., Davidson D. C. & Jackson, I. J. (1992) Develop- 
35. Pawelek, J. M., Chakraborty & Orlow, S. J. (1992) J. Invest. 
R.(1991) Nucleic Acids Res. 19, 3799-3804. 
S. (1992) Biochem. Biophys. Res. Commun. 184,568-575. 
ment (Camb.) 115, 1111-1119. 
Dermatol. 98. 630. 
